CASE STUDY company is building on its scientific legacy by marketing an antibiotic for difficult-to-treat Gram-negative bacterial infections, developing investigational antivirals for COVID-19 prevention and treatment and, through its subsidiary, Qpex Biopharma, advancing a portfolio of antibiotics for resistant bacteria. Beyond infectious disease, the company pipeline includes clinical programs in rare disease, acute ischemic stroke and oncology.
In many ways, the solution sold itself.
Jay Upchurch, Executive Vice President and CIO at SAS, offered further insight on the partnership and its innovative impact.
What were the technical challenges inherent in implementing the SAS solution with Shionogi Inc.?
Jay Upchurch, Executive Vice President and CIO at SAS
The main challenge Shionogi was facing going into implementation was the incredible amount of data the company had. We were wellpositioned to help it through this, since SAS is well-known for its ability to access, manage and analyse large amounts of data.
How did SAS work with Shionogi in implementing the solution? a common struggle for companies is how to quickly maximise their AI investments to meet their corporate aspirations. That’ s where SAS Viya Essentials comes in. It provides an easy-touse way for customers to get the trusted answers they need in a fast, flexible and cost-effective way so they can stay ahead of their competition.”
Shionogi inc., a US subsidiary of Shionogi & Co. and a key player in the pharmaceutical manufacturing space, needed a trusted vendor to manage its data workload with cost control in a hosted environment and turned to SAS.“ SAS Viya Essentials enables us to process larger data sets with speed and efficiency so we can continue to generate key insights, accelerate business success and build on our scientific legacy," said Anindita Sinha, VP of Commercial Operations at Shionogi Inc.
The manufacturer has been harnessing the full potential of science to improve patients’ lives since 1878. Over the past six decades, Shionogi has discovered several novel antibiotics and medications for HIV and influenza. Today, the
We worked closely with Shionogi throughout the implementation. Our standard deployment process is robust and commits dedicated staffing to the project from start to finish, so we’ re available for any needs throughout the whole process.
What future technical requirements does SAS foresee evolving over the life of the partnership?
We expect the amount of data Shionogi wants to analyse will continue to grow over time. We look forward to continuing our close working relationship with the team as they use the power of SAS to make data-driven decisions to meet their business goals.
Anindita Sinha, VP of Commercial Operations at Shionogi Inc. discusses her experience with SAS and the overall benefit.
What impact has the rollout of the SAS solution had on Shionogi so far?
The most immediate impact has been within the analytics organisation. Teams are now able to run more complex analyses on data sets that were previously too large or demanding for our on-premises solution to handle efficiently. This increased speed and agility has enabled us to
www. intelligentcio. com
INTELLIGENT CIO APAC
15